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Abstract
The use of allogeneic hematopoietic stem cell transplantation (HSCT) to cure multiple disorders is 
limited by deficiency and dysregulation of T-cells. Here we report a biomaterial-based scaffold 
that mimics features of T-cell lymphopoiesis in the bone marrow. The bone marrow cryogel 
(BMC) releases bone morphogenetic protein-2 to recruit stromal cells, and presents the Notch 
ligand Delta-like ligand-4 to facilitate T-cell lineage specification of mouse and human 
hematopoietic progenitor cells. BMCs subcutaneously injected in mice at the time of HSCT 
enhanced T-cell progenitor seeding of the thymus, T-cell neogenesis and diversification of the T-
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cell receptor repertoire. Peripheral T-cell reconstitution increased ~6-fold in mouse HSCT and ~2-
fold in human xenogeneic HSCT. Furthermore, BMCs promoted donor CD4+ regulatory T-cell 
generation and improved survival after allogeneic HSCT. Compared with adoptive transfer of T-
cell progenitors, BMCs increased donor chimerism, T-cell generation and antigen-specific T-cell 
responses to vaccination. BMCs may provide an off-the-shelf approach for enhancing T-cell 
regeneration and mitigating graft-versus-host disease in HSCT.
Introduction
T-cells are critical helper, effector and regulatory immune cells that are essential for life. 
Reduced T-cell numbers and functional deficiencies are causally implicated in diseases 
ranging from congenital immunodeficiency to autoimmune and impaired immune 
surveillance disorders 1, 2. In allogeneic HSCT, there is a marked deficiency in T-cell 
generation, which renders patients susceptible to infectious agents and may contribute to 
graft-versus-host disease (GVHD)3. These complications can be fatal and limit the use of 
HSCT in settings where it can be curative. Balanced reconstitution of the naïve helper and 
effector T-cell subsets, along with the restoration of the T-cell receptor repertoire remains a 
significant unmet clinical need4.
New T-cell regeneration from transplanted hematopoietic cells requires the availability of an 
adequate pool of T-cell progenitors5 arising from bone marrow and adequate thymic 
function6. While there is currently no clinical standard for enhancing T-cell generation in 
vivo, most efforts have focused on using cytokines and cell-based therapies from the post-
bone marrow phases of T-cell lymphopoiesis. However, in clinical trials, T-cell expansion 
cytokines IL-7 and IL-27 increased primarily mature T-cell subsets8, and IL-2 was further 
limited by toxicity9. In contrast, the administration of IL-22 has been shown to enhance 
early thymocyte recovery in preclinical mouse studies10. Alternatively, adoptive donor T-cell 
infusion has been used to provide antigen-specific T cell protection against commonly 
encountered pathogens11, 12, but has been associated with a transient response, increased 
risk of GVHD, and T-cell exhaustion. The above strategies are all limited by the availability 
of an adequate pool of T-cell progenitors to promote thymus-dependent T-cell generation. T-
cell precursors can be robustly generated ex-vivo by the activation of Notch signaling, and 
co-administration of these cells with HSCT improves thymopoiesis and thymic architecture 
without exogenously co-administered cytokines 13–15. However, ex-vivo cell culture to 
generate sufficient progenitors is laborious and only a transient enhancement in 
thymopoiesis of donor cells has been demonstrated. Thus, the widespread clinical translation 
of this approach would likely be complex.
Seeking to develop a broadly applicable technology, we focused on the pre-thymic bone 
marrow resident common lymphoid progenitors (CLPs), which have the capacity to 
differentiate into naïve T-lymphocytes when Notch signaling is activated, and are a major 
source of thymopoiesis16–18. The stromal component of the bone marrow niche that 
enhances T-cell lineage specification consists of osteocalcin-expressing bone marrow 
stromal cells producing delta-like ligand-4 (DLL-4), which provide a functional 
microenvironment critical for generating T-cell competent CLPs19. These stromal cells are 
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damaged by the process of pre-conditioning which likely impacts their T-cell lineage-
instructive function. Additionally, the clinical experience with AIDS patients indicates that 
the adult thymus has the capacity to markedly improve in cellular composition and T-cell 
neogenesis despite prior dysfunction and atrophy20. These prior findings supported the 
development of a niche based on specific biologic aspects of T-cell lymphopoiesis in the 
bone marrow. We hypothesized that a T-cell lymphopoietic bone marrow niche might be 
engineered to foster production of T-cell progenitors in vivo that emigrate into the native 
thymus and thereby undergo host driven selection to create a more balanced and broad 
immune repertoire. We created an injectable, biomaterial-based bone marrow cryogel 
(BMC) scaffold that promotes T-cell development in vivo by integrating molecular signals 
that are presented in the bone marrow niche. The BMC comprises a macroporous hydrogel-
based scaffold permitting cellular infiltration. It releases bone morphogenetic protein-2 
(BMP-2) to facilitate the recruitment of host stromal cells and their osteolineage 
differentiation and presents bioactive Notch ligand DLL-4 at predefined densities to 
infiltrating hematopoietic cells. These T-lineage cues enhanced thymic seeding of 
progenitors and enabled donor T-cell reconstitution after syngeneic (syn) and allogeneic 
(allo) HSCT in mice. The BMC-reconstituted T-cells were functional, with a diverse T-cell 
receptor (TCR) repertoire, and reduced induction of GVHD.
Results
Macroporous Bone Marrow Cryogels (BMCs) differentiate hematopoietic progenitor cells in 
vitro
The scaffold-based Alginate-PEG BMC is a macroporous hydrogel with interconnected 
pores 50–80μm in diameter (Fig. 1a-c). DLL-4 was incorporated into the polymer backbone 
to promote the T-cell lineage program in hematopoietic progenitor cells17. To enable de novo 
bone formation21, BMP-2 was added to the reaction mixture prior to cryo-polymerization 
for subsequent release in soluble form in vivo. These cryogels present both immobilized 
(DLL-4) and soluble (BMP-2) cues, unlike previous cryogels which were solely designed 
for controlled release of proteins22. In this work, the BMCs additionally support the growth 
of bone and hematopoietic tissue. In vitro BMP-2 release (encapsulation efficiency 90%) 
displayed an initial burst of about 5% of the loaded amount, and then released in a sustained 
manner (Fig 1d). Less than 1% of the total loaded DLL4 was detected in the supernatant, 
and modified DLL-4 had similar binding kinetics to that of the unmodified protein (Fig. 1e). 
In the pooled release samples, over 90% of the bioactivity of the released BMP-2, relative to 
freshly reconstituted BMP-2 was retained (Supplementary Figure 1a). The bioactivity of 
BMP-2 ranged from 95% at Day 3 of release to ~85% at Day 12, confirming the released 
BMP-2 is highly active (Supplementary Figure 1b). The highest in vitro bioactivity of 
DLL-4 was found at the early time points, at Days 0 and 10 (Supplementary Figure 1c,d). 
The bioactivity decreased at subsequent time points but was still above baseline after 3 
months. To measure the capacity of the BMC to induce the differentiation of hematopoietic 
progenitor mouse and human cells via Notch signaling, primary lineage depleted bone 
marrow cells from mice and cord-blood derived human CD34+ hematopoietic cells were 
cultured in the BMC (Fig. 1f). The expansion of the common lymphoid progenitors 
saturated at 1% functionalization of the MA-COOH groups on the polymer backbone with 
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MA-DLL4, corresponding to approximately 6μg MA-DLL4 per gel and this condition was 
selected for further evaluation. There were no significant differences in the fold expansion 
and viability numbers of overall human or mouse cells in any of the experimental conditions 
analyzed (Supplementary Figure 1e, f). However, the fraction of lymphoid progenitor cells 
was enhanced only when DLL-4 was incorporated in the BMC, alone or in combination with 
BMP-2 (Fig. 1g).
BMCs form a bone nodule with features of hematopoietic tissue in vivo
The BMC was next analyzed for its ability to induce the trafficking of host and transplanted 
cells in a mouse model of HSCT. After lethal total body irradiation (L-TBI) mice were 
transplanted intravenously with lineage-depleted hematopoietic cells (5 × 104; ~93% lineage 
depleted, Supplementary Fig. 2a) isolated from donor mice bone marrow, and the BMCs 
(without cells) were simultaneously injected in the subcutaneous tissue of the dorsal flank 
(Fig. 2a). To grossly quantify cell infiltration in the BMCs, the size of each subcutaneous 
nodule was measured over a period of 6 weeks (Fig. 2b). In the BMC with BMP-2, nodule 
size rapidly increased to approximately 3 times over the initial volume after the first 10 days 
post-transplant and was substantially infiltrated with donor hematopoietic cells (Fig. 2c), 
forming a local bone nodule over a period of approximately 2 weeks, (Fig. 2d, e). Notably, 
bone formation was accompanied by vascularization, the DLL-4 remained accessible, and 
bone was restricted to the BMC scaffold, demonstrating the control afforded by the BMC 
over this process at an ectopic site (Fig. 2f-j, Supplementary Fig. 2b, Supplementary Note 
1).
BMCs recruit and expand host stromal and transplanted hematopoietic cells
We assessed the infiltration and cell composition of the transplanted hematopoietic cells in 
the BMC at various time points post-transplant. The donor GFP+ cells expanded when 
BMP-2 was included but not in the presence of DLL-4 alone (Fig. 3a, Supplementary Figure 
2c). The stromal cells populating the BMCs and the native bone marrow were found to be 
similar, there was no difference in the engraftment of hematopoietic cells in native bone 
marrow of BMC-treated and non-treated mice, and SDF-1α and interleukin-7 concentrations 
were similar in the BMCs and native bone marrow (Supplementary Figure 2d-g, 
Supplementary Note 2). At the later time points (> 5 days post transplant), more primitive 
donor hematopoietic cells (HSCs and LMPPs) were quantified in the BMC. At Day 14, 
between 6 and 7 million total GFP+ cells were quantified in the BMCs containing single 
factor BMP-2 or dual factor BMP-2 and DLL-4. Over 80% of cells were CD11b+ myeloid 
cells in both groups. However, the CLP fraction in the transplanted donor cells expanded 
only within dual factor BMCs, resulting in a ~100-fold increase relative to BMCs with only 
BMP-2 at 2-weeks post-transplant (Fig. 3a). At 6-weeks post-transplant CLPs were ~10-fold 
higher in the dual factor BMCs, of which approximately 30% and 70% respectively were in 
the T-cell competent Ly6D- subset (Fig. 3b). Progenitor T-cells from the bone marrow 
migrate to the thymus to differentiate into naïve T-cells. To directly assess whether cells 
from the BMC migrate to the thymus, the dual factor BMC in concert with stem cell therapy 
was delivered into an initial set of lethally irradiated mice (Fig. 3c, d). The dual BMC was 
then explanted from these mice at day 10, and surgically transplanted into sublethally 
irradiated recipients subcutaneously in the dorsal flank. On day 20 post-BMC 
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transplantation, the donor GFP+ and host cells in the thymus of these mice were quantified. 
GFP+ DP, SP CD4+ and SP CD8+ cells were quantified in the thymus of BMC-transplanted 
recipient mice confirming migration of T-cell progenitor cells from the BMC to the thymus. 
In a separate study, Dual BMC treatment resulted in a greater enhancement of the number of 
ETPs in the thymus when compared to a 10-fold increase in the administered transplant cell 
dose without BMC (Fig. 3e). The Dual BMC also significantly outperformed bolus delivery 
of the factors placed in the BMC, and the BMP-2 only BMC, in generating thymocyte 
subsets over time (Fig. 3f-k, Supplementary Note 3).
BMCs enhance T-cell regeneration after HSCT and mitigate GVHD
In the peripheral blood of mice treated with the dual functionalized BMC, acceleration in T-
cell reconstitution was observed approximately 4 weeks post-transplant, but no significant 
difference was observed in B-cell or myeloid cell reconstitution (Fig. 4a, Supplementary Fig. 
3a, b). An analysis of T-cell subsets in the blood, spleen and bone marrow indicated that the 
homeostatic CD4+:CD8+ T-cell ratio was restored in mice with the dual functionalized 
BMCs after 30 days post-transplant in the spleen and bone marrow, and 40 days post-
transplant in the peripheral blood (Fig. 4b-d). When the BMC treatment was used in the 
context of HSCT after sublethal total body irradiation (SL-TBI), there was enhanced T-cell 
reconstitution (Fig. 4e-j, Supplementary Figure 3c, d). At 28 days-post transplant the donor 
chimerism and absolute number of DP donor thymocytes were 1.5-fold and 2-fold higher 
respectively in BMC treated mice relative to mice that received just the transplant (Fig. 4e). 
There was also a higher donor chimerism and absolute number of donor-derived SP4 (by 2-
fold and 3-fold respectively) and SP8 (by 1.7-fold and 15-fold respectively) thymocytes 
(Fig. 4f, g). In the periphery, the donor chimerism was higher in the CD4+ (by 3.5-fold) and 
CD8+ (by 2.5-fold) T-cells. No difference was observed in the chimerism or absolute 
number of B-cells.
We next assessed the rate of human T-cell reconstitution using an established xenogeneic 
NSG-BLT mouse model23. In BMC-treated NSG-BLT mice, there was an early 
enhancement in the initial rate of T-cell reconstitution, and a modest, transient reduction in 
the rate of B-cell reconstitution (Fig. 5a, b), with transiently fewer pre-B cell CFUs in the 
bone marrow of BMC-treated NSG-BLT mice (Supplementary Fig. 4). The peripheral 
CD4+:CD8+ T-cell ratio was stabilized in BMC-treated mice between 50 and 60 days post-
transplant, whereas the CD4+ compartment in control NSG-BLT was not fully reconstituted 
(Fig. 5c). Strikingly, the enhanced rate of T-cell reconstitution did not accelerate the rate of 
GVHD-related death. Instead, NSG-BLT mice that received the dual functionalized BMC 
survived longer than the NSG-BLT mice (Fig. 5d). In BMC-treated NSG-BLT mice, 
CD4+FoxP3+ regulatory T-cells (Treg) were 2-fold higher in the thymus and spleen of BMC-
treated mice at 50 days post-transplant in this model (Fig. 5e, Supplementary Figure 5a). A 
similar enhancement in survival was observed in an allogeneic MHC-mismatch HSCT 
mouse model that received the BMC (Figure 5f), and donor-derived CD4+FoxP3+ Treg were 
5-fold and 4-fold higher in the thymus and spleen, respectively, of BMC-treated mice 15 
days post-transplant in this model (Fig. 5g).
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We next compared our BMC treatment to a widely studied T-cell progenitor infusion 
approach, consisting predominantly of DN2 and DN3 precursors (> 90%) generated ex vivo 
using OP9-DL1 feeder cells (Supplementary Figure 5b). At 28 days post-HSCT, donor 
chimerism was significantly higher in the BMC-treated mice in the DP, SP4 and SP8 
thymocyte populations (Figure 5h-j). In the spleen, donor chimerism was higher for both 
CD4+ and CD8+ T-cells, and higher absolute numbers of donor CD4+ and CD8+ T-cells 
were found with BMC-treatment (Figure 5k, l).
BMCs facilitate the enhancement of T-cell receptor diversity and function of regenerated T-
cells
The diversity in T-cell receptors (TCR diversity) is produced by stochastic somatic 
recombination of gene segments in the thymus. In dual BMC treated mice, the thymus 
cellularity and the thymus weight were significantly higher than transplant-only controls 
upto ~6 weeks post-transplant (Supplementary Figure 6a, b). To characterize whether the 
increase in thymic cellularity also enhanced the functionality and diversity of the 
regenerated T-cells in syngeneic transplants, we quantified TCR excision circles (TRECs), 
which are a signature of TCR rearrangement, and conducted a TCR repertoire analysis. 
TREC number in the thymus of dual BMC-treated mice 1 month after transplantation were 
similar to that in non-irradiated control mice, and both were greater than in transplant only 
mice and BMP-2 BMC treated mice (Fig. 6a). In the spleen, an overall lower number of 
TRECs were noted in the same groups relative to the non-irradiated control, but mice treated 
with dual BMCs still had a higher TREC count relative to the transplant only and single 
factor BMP-2 BMC groups (Figure 6b). We next evaluated the diversity of the TCR V and J 
segments in the CDR3 beta chain of the BMC treated and transplanted mice 30 days post-
HSCT using the Simpson’s index (SI), which takes into account the number of T-cell clones 
present, as well as the relative abundance of each clone. The SI of mice with the dual 
functional BMC was 40% that of non-irradiated control mice, whereas the SI in mice 
administered the transplant alone or with BMP-2 BMC were lower (16% and 8%, 
respectively) (Fig. 6c). In HSCT, the lack of naive T cells with a broad TCR repertoire has 
been associated with increased risk of immunological complications and opportunistic 
infections24. The recovery of a greater number of TRECs in the thymus and periphery of 
dual BMC treated mice mirrors the enhancement in thymopoiesis. Relatively high 
frequencies of specific TCR clones were also observed in mice treated with dual BMCs, but 
a greater overall diversity suggested a more balanced thymus-derived reconstitution.
To measure the capacity of regenerated T-cells to respond in an antigen-specific manner, 
syngeneic transplants were vaccinated and subsequently challenged with a model protein 
ovalbumin (OVA) 30 days after transplantation (Fig. 6d). OVA epitope (SIINFEKL)-specific 
CD8+ T-cells were significantly higher in mice that received the dual functional BMC, as 
compared to transplanted mice that did not receive the BMC or that received the BMC with 
BMP-2 only (Fig. 6e). Similarly, in dual BMC-treated mice that received the allogeneic 
transplant, the donor antigen-specific T-cell response was approximately 3-fold higher, as 
compared to that resulting from the pro-T-cell therapy approach (Fig. 6f). We found that the 
production of interferon (IFN)-γ and tumor necrosis factor–α (TNF-α) upon ex vivo 
stimulation was comparable for donor CD4+ and CD8+ T-cells in the BMC treatment and T-
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cell progenitor treatment groups at Day 22, but a significantly greater fraction of T-cells 
from the BMC-treated group produced these factors at Day 42 (Fig. 6g-h). The robust 
antigen-specific generation of CD8+ T-cells after vaccination in BMC treated mice post-
HSCT suggests that the BMC treatment has the potential to be used in combination with 
post-HSCT vaccination.
Discussion
Here, we demonstrate that a cell-free biomaterial-based BMC mimicked key features of the 
T-cell lymphopoietic bone marrow niche and promoted the regeneration of immune 
competent T-cells after hematopoietic stem cell transplantation. Subcutaneously 
administered BMCs interfaced with the host vasculature to form a host-device interface and 
presented lineage-instructive cues to donor recruited progenitor cells in vivo. It is well 
established that BMP-2 induces osteolineage differentiation of recruited mesenchymal cells 
and indirectly promotes rapid neoangiogenesis25. In this work, we observed early 
neoangiogenesis, followed by maturation of the vasculature to densities consistent with 
those observed in endogenous bone marrow26. The finding of various hematopoietic and 
stromal progenitor populations quantified within the BMC are consistent with previous 
observations of hematopoiesis occurring within an ectopic bone nodule27, 28. The 
incorporation of bioactive Notch ligand DLL-4 on the polymer scaffold promoted an early 
enhancement in the generation of T-cell progenitors in the BMC and led to a significant 
increase in the number of thymic progenitors relative to controls receiving lineage-depleted 
bone marrow grafts, and the controls were consistent with established models of syngeneic- 
and allogeneic-HSCT29, 30. This finding is supported by the observation of enhanced 
generation of TRECs, the increased complexity of the TCR repertoire and the increased 
vaccination efficacy.
The BMC approach is distinct conceptually and in practice from other strategies to promote 
post-HSCT T-cell regeneration and its relevance in HSCT is supported by the preclinical 
studies in this work. It resulted in a higher number of T-cell progenitors and functional T-
cells in the thymus and the periphery when used with a 10-fold lower dose relative to T-cell 
progenitor infusion. The BMC treatment varies from other methods in that it can be 
administered at the time of HSCT. In contrast, T-cell progenitors are produced in vitro from 
donor hematopoietic cells over 2–4 weeks, have complex cell culture requirements in pre-
clinical models and are patient specific. By providing the T-cell promoting cues to the 
transplanted HSCs in vivo without the need for ex-vivo culture, the BMC approach may be 
an off-the-shelf product, avoid the considerable infrastructure needed for cell manufacturing 
31
 and may complement the activities of cytokine therapies. When a lower radiation dose 
was used prior to HSCT, the BMC modestly enhanced T-cell reconstitution in the periphery, 
but significantly increased donor-derived T-cell generation in the thymus and donor T-cell 
chimerism. The finding suggests the application of the BMCs will be relevant in settings of 
lower intensity HSCT.
The enhancement in the reconstitution of human T-cells in xenogeneic NSG-BLT mice was 
accompanied by a modest and transient reduction in B-cell reconstitution, consistent with a 
corresponding decrease in pre-B CFUs. While this humanized mouse model is widely 
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accepted for human immune cells, it is also known that key mouse cytokines are inefficient 
at inducing hematopoiesis including the development of human B-cells from human CD34+ 
cells in this model32. It is likely that the Notch activation of the fraction of the transplanted 
cells, which seed the BMC enhances T cell specification at the expense of B cell 
specification. However, the transient reduction in B-cell production is modest and unlikely to 
be of clinical significance.
The formation of a bone nodule is restricted to the geometry of the scaffold, consistent with 
previous reports of scaffold-induced bone formation, which has been well tolerated in many 
species, including non-human primates33 and in humans34, 35. Our clinical experience with 
other scaffold-based systems indicates that the size of the device may remain constant 
between species36. Even with the larger growth factor dose that may be necessary for use in 
humans, we anticipate that the controlled release provided by this polymer-based hydrogel 
system would allow one to use several orders of magnitude lower BMP-2 than is currently 
used in the clinic, as high doses have been associated with undesirable side effects37. After 
T-cell regeneration, the BMC may be readily removed similar to other devices that are often 
used in HSCT or made with biodegradable materials to resorb 38.
CD4+ T-cell recovery after allogeneic HSCT is usually delayed, leading to an inversion of 
the normal CD4/CD8 ratio39. In BMC treated mice, there was a more balanced 
reconstitution of T-cells and an enhancement in donor CD4+ regulatory T-cells (Treg) in the 
thymus and the spleen of humanized and allogeneically transplanted mice. Given the key 
role of donor Treg in GVHD suppression40, BMC-mediated enhancement of donor Treg 
generation likely contributed to the mitigation of GVHD-like pathology and the enhanced 
survival of mice, potentially through BMP-2 regulation of TGF-beta family proteins, which 
are key regulators of Treg expansion41. Moreover, the time course in the allogeneic GVHD 
model is consistent with at least some of the BMC role being due to an effect on pre-existing 
T-committed or mature T cells.
In sum, these findings suggest that the BMC represents a simple to administer, off-the-shelf 
system that can enhance T cell regeneration after HSCT. If the BMC system performs 
similarly in a human context, it may be a means of abrogating the immunological 
complications and opportunistic infections that limit clinical application of potentially 
curative HSCT.
Methods
General methods and statistics.
Sample sizes for animal studies were based on prior work without the use of additional 
statistical estimations42, 43. Results were analyzed by using one-way ANOVA with a Tukey 
post hoc test using GraphPad Prism software. Where ANOVA was used, variance between 
groups was found to be similar by Bartlett’s test. Survival curves were analyzed by using the 
log-rank (Mantel–Cox) test. Alphanumeric coding was used to blind pathology samples and 
blood counting.
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Materials
UP LVG sodium alginate with high guluronate content was purchased from ProNova 
Biomedical; 2-morpholinoethanesulfonic acid (MES), sodium chloride (NaCl), sodium 
hydroxide (NaOH), N- hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide hydrochloride (EDC), 2-aminoethyl methacrylate hydrochloride (AEMA) and 
acetone were purchased from Sigma-Aldrich. ACRL-PEG-NH2 (3.5 kDa) and 4arm PEG 
Acrylate (10 kDa) were purchased from JenKem Technology.
Bone Marrow Cryogel (BMC) fabrication
The bone marrow cryogel was made following a previously described technique with some 
modifications44. Methacrylated alginate (MA-alginate) was prepared by reacting alginate 
with AEMA. Sodium alginate was dissolved in a buffer solution (0.6% (wt/vol), pH ∼6.5) of 
100 mM MES buffer. NHS and EDC were added to the mixture to activate the carboxylic 
acid groups on the alginate backbone followed by AEMA (molar ratio of 
NHS:EDC:AEMA=1:1.3:1.1), and the solution was stirred at room temperature (RT) for 24 
h. The mixture was precipitated in acetone, filtered and dried in a vacuum oven overnight at 
RT. Alginate- PEG BMCs were synthesized by preparing a 2.5 wt% solution of MA-alginate 
and 4arm PEG Acrylate macromonomers (molar ratio MA-alginate: 4arm PEG Acrylate = 
4:1) in deionized water and subsequently adding tetramethylethylenediamine (TEMED) 
(0.5% (wt/vol)) and ammonium persulfate (APS) (0.25% (wt/vol)). ACRYL-PEG-NH2 was 
conjugated with the Delta-like ligand 4 (DLL-4) (R&D Systems) using carbodiimide 
chemistry (molar ratio of NHS:EDC:DLL4 = 1:1.3:1.1). BMP-2 (R&D Systems) was added 
to the polymer solution before cryopolymerization. All precursor solution was precooled to 4 
°C to decrease the rate of polymerization before freezing. After addition of the initiator to 
the prepolymer solution, the solution was quickly transferred onto a precooled (−20 °C) 
Teflon mold. After overnight incubation, the gels were thawed and collected in petri dishes 
on ice. For scanning electron microscopy (SEM), BMCs were incubated in increasing 
concentration of freshly prepared ethanol solution (30, 50, 70, 90 and 100%) for 20 minutes 
each. BMCs were then incubated in hexamethyldisilazane (Electron Microscopy Sciences) 
for 10 min and dried in a desiccator/vacuum chamber for at least 1 hour prior to mounting 
them for SEM. Dried BMCs were adhered onto sample stubs using carbon tape and coated 
with a platinum/palladium in a sputter coater. Samples were imaged using secondary 
electron detection on a Carl Zeiss Supra 55 VP field emission scanning electron microscope 
(SEM).
Biomolecule release quantification
The stock concentration of the BMP-2 was known from the manufacturer and verified using 
ELISA. To determine the release kinetics encapsulation efficiency of BMP-2 and to confirm 
stable conjugation of DLL-4, the BMCs were incubated in 1ml of sterile PBS at 37 °C with 
shaking. Media was replaced periodically. Released agents in the supernatant were detected 
by ELISA (Peprotech). The samples were released until no more BMP-2 was detectable in 
the release medium. Subsequently, the cryogel was digested using at least 1000U of the 
enzyme Alginate Lyase. The digested product was analyzed for BMP-2 using ELISA. The 
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amounts of BMP-2 and DLL-4 in the cryogel and release medium were compared with the 
known amount of loaded BMP-2 and DLL-4 to calculate the encapsulation efficiency.
Biomolecule activity assays
Alkaline phosphatase activity assay for BMP-2 bioactivity—MC3T3-E1 Subclone 
4 cells were used to conduct an alakaline phosphatase assay as previously described45. Cells 
were cultured under different experimental conditions: (1) growth medium, (2) 
differentiation medium supplemented with BMP-2 release from BMCs and (3) Native 
BMP-2.
Notch activation assay for DLL-4 bioactivity—To quantify the in vitro bioactivity of 
DLL-4 after exposure to serum proteins, which could deactivate this morphogen in vivo, a 
previously characterized Notch reporter cell line, CHO-K1 +2xHS4-UAS-H2B-
Citrine-2xHS4 cH1 +hNECD-Gal4esn c9, a gift from M. Elowitz lab, was used46, 47. These 
cells were grown in Alpha MEM Earle’s Salts (Irvine Scientific) supplemented with 10% 
Tet System Approved FBS (Clontech), 100 U/ml penicillin −100 ug/ml streptomycin – 0.292 
mg/ml L-glutamine (Gibco), at 37ºC in the presence of 5% CO2 under a humidified 
atmosphere. BMCs both with and without the DLL-4 were incubated in 96-well plates with 
the complete cell culture medium, without cells. At pre-determined time intervals (up to 3 
months), twenty-thousand Notch reporter cells were seeded in the wells on the BMCs. After 
24 hours, confocal microscopy was performed using a Zeiss LSM 710 confocal system. The 
colorimetric output in response to binding with Notch ligand DLL-4 was quantified and used 
as an indicator of DLL-4 bioactivity in the scaffold (Supplementary Figure 1c). In particular, 
the total YFP fluorescence of each cell in a field of view (50 – 100; 4–5 field of views 
encompassing over 80% of the gel surface) was calculated and background fluorescence was 
subtracted. The median YFP fluorescence was calculated and divided by the median 
fluorescence of the cells seeded on the BMCs without DLL-4 and reported.
Affinity determination by surface plasmon resonance—Dissociation constants of 
wild-type DLL4 and MA-DLL4 for Notch1 were determined by surface plasmon resonance 
using a BIAcore T200 instrument (GE Healthcare) as described previously34. Briefly, 
biotinylated, recombinant Notch1 were immobilized on a streptavidin coated sensor chip 
(GE Healthcare). Increasing concentrations of wild-type of methacrylated DLL4 proteins in 
buffer were flowed over the chip at 20°C. Binding and dissociation phases were performed 
at 10µl/min for 120 seconds and 60 seconds, respectively. Steady-state binding curves were 
fitted using the BIAcore evaluation software to a 1:1 Langmuir model to determine the Kd.
In vitro cell culture in Bone Marrow Cryogel (BMC)—Mouse BM cells were 
harvested from the limbs. Crushed tissue and cells were filtered through a 70-micron mesh. 
A single cell suspension was prepared by passing the cells once through a 20-gauge needle. 
Total cellularity was determined by counting cells using a hemacytometer. BM cells were 
depleted of mature immune cells (expressing CD3-ε, CD45R/B220, Ter-119, CD11b or 
Gr-1) by magnetic selection (BD Biosciences). We incubated cells with a mix of Pacific 
Blue-conjugated lineage antibodies (antibodies to CD3, NK1.1, Gr-1, CD11b, CD19, CD4 
and CD8) and with Sca-1– and c-kit–specific antibodies. We isolated hematopoietic cells 
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(Lin−Sca-1hic-kithi) using a FacsAria cell sorter (BD). Sorted cells were ≥ 95% pure. Human 
cord-blood derived CD34+ cells were purchased (Allcells) and expanded for seven days 
using expansion supplements (Stemcell Technologies). CD34+ cells were isolated using a 
positive selection kit (StemCell Technologies). 96 well plates were pre-coated with Pluronic 
F127 (Sigma). Each BMC was individually placed in a well of the 96 well plate. Ten 
thousand mouse or human cells, isolated as described above were added to the same well in 
a 200μl volume of RPMI (with L-Glutamine) 1640 with 10% fetal bovine serum (FBS) and 
1% of antibiotic and anti mycotic solution (containing penicillin, streptomycin and 
amphotericin B). For mouse cells, the media was supplemented with 10 ng/ml of stem cell 
factor (SCF; R&D Systems), 10 ng/mL FMS-like tyrosine kinase 3 ligand (Flt3L; R&D 
Systems) and 1 ng/mL interleukin-7 (IL-7; R&D Systems) with a 50% medium exchange 
step at day 2, 4 and 6. For human cells, the media was supplemented with 100 ng/mL SCF, 
100 ng/mL Flt3L, 100 ng/mL TPO (R&D Systems), and 100 ng/mL IL-7 (R&D Systems). 
After one week of culture, cells were isolated by digesting the BMC with 1mg/ml Alginate 
Lyase (Sigma). The solution was passed through a 70-micron filter and cells were processed 
for FACS analysis as described below.
BM transplantation and blood analysis
All animal work was approved by the Harvard Institutional Animal Care and Use Committee 
and followed the National Institutes of Health guidelines and relevant ethical regulations. 
C57BL/6 (B6, H-2b), BALB/c (H-2d), C57BL/6 (CD 45.1+), CByJ.B6-Tg(UBC-
GFP)30Scha/J (GFP) and NSG mice (Jackson Laboratories) were female and between 6 and 
8 weeks old at the start of the experiment. All mice within each experiment were age-
matched and no randomization was performed. Pre-established criterion for animal omission 
was failure to inject desired cell dose in transplanted mice and death due to post-surgical 
complications in humanized mice. Health concerns unrelated to the procedure (e.g., 
malocclusion, severe dermatitis) were criteria for omission and euthanasia.
Transplant models
All TBI experiments were performed with a Cs-137 γ-radiation source. Sublethal-TBI (SL-
TBI, B6 recipient), 1 × 500 cGy + 5 × 105 lineage-depleted bone marrow cells; syngeneic 
HSCT (syn-HSCT, B6 recipient) 1 × 1000 cGy + 5 × 104 to 5 × 105 (as indicated in the 
figures) lineage depleted GFP BM cells; allogeneic-HSCT with GVHD (BALB/c MHC-
mismatched recipient) 1 × 850 cGy + 5 × 105 lineage depleted GFP BM cells + 1 × 106 GFP 
splenocytes; allogeneic-HSCT without GVHD (BALB/c MHC-mismatched recipient) 1 × 
850 cGy + 5 × 105 lineage depleted GFP BM cells or 5 × 106 in vitro generated GFP T-cell 
progenitors + 103 syngeneic HSCs as described elsewhere without modification48. 
Humanized BLT (bone marrow‒liver‒thymus) mouse studies were conducted by the MGH 
and Ragon Institute Human Immune System Mouse Program, with Institutional IACUC 
approval as described previously23. BM cells for transplantation or analysis were harvested 
by crushing all limbs or one femur, respectively and processed as described above. While the 
mice were anesthetized, they received subcutaneous injections of two BMCs, which were 
suspended in 0.2 ml of sterile PBS, into the dorsal flank by means of a 16-gauge needle. One 
BMC was injected on each side of the spine and positioned approximately midway between 
the hind and forelimbs. Subcutaneous nodule size was quantified over time by measuring the 
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nodule length, width and height using a caliper. All cohorts of mice (typically 10 mice/
group) were serially bled. White blood cell, hemoglobin, red blood cell, platelet, and 
hematocrit levels were quantified by CBC analysis (Abaxis VetScan HM5).
For directly assessing whether cells from the BMC migrate to the thymus, the dual factor 
BMC in concert with stem cell therapy was delivered into an initial set of lethally irradiated 
mice (B6 recipients receiving 1000 cGy L-TBI and 5 × 105 lineage depleted GFP BM cells 
with dual factor BMC. 10-days post-HSCT, the dual factor BMC was explanted and 
immediately surgically transplanted in the subcutaneous pocket of a second set of B6 mice 
which had received 500 cGy SL-TBI 48-hours prior without any additional cell 
transplantation. 20-days post surgery, mice were sacrificed and the thymocytes were 
analyzed in these mice.
Flow cytometry (FACS) analysis
Anti-mouse antibodies to CD8-α (53–6.7), CD3-ε (145–2C11), B220 (RA3–6B2), CD11b 
(M1/70), CD25 (PC61), CD117 (2B8), Sca-1 (D7), CD127 (A7R34), and anti-human 
antibodies to CD45 (H130), CD3 (HIT3a), CD4 (SK3), CD19 (HIB19), CD34 (581), CD38 
(HB-7) and CD7 (CD7–6B7), IFN-γ (XMG1.1), TNF-α (MP6-XT22) and the 
corresponding isotype antibodies were purchased from BioLegend. Anti-human CD8 (RPA-
T8) was purchased from BD Biosciences. CD44 (IM7) was purchased from eBioscience. 
SIINFEKL tetramer (Alexa Fluor 647 H-2Kb OVA) were obtained from the NIH Tetramer 
Core Facility. All cells were gated based on forward and side-scatter characteristics to limit 
debris including dead cells. Antibodies were diluted according to the manufacturer’s 
suggestions. Cells were gated based on fluorescence minus one controls, and the frequencies 
of cells staining positive for each marker was recorded. For quantifying T, B, and myeloid 
cells, blood samples were red blood cell–lysed and stained with anti-CD45, -B220, -CD3, -
CD4, -CD8, and –CD11b antibodies, and absolute numbers of T, B, and myeloid cells were 
calculated using flow cytometry frequencies and white blood cell values obtained by CBC 
analysis. Analysis was based on donor events within the CD45+ for blood cells and the 
CD45- gate for stromal cells.
Bone, Fat Quantification and Histology
After euthanasia, BMCs and tissues were explanted. For quantification of bone using bone 
alkaline phosphatase (BALP), the BMCs and femurs were crushed and homogenized and 
strained through a 70 micron filter. Subsequently, a BALP ELISA kit (Creative Diagnostics) 
was used to quantify the BALP by following the manufacturer’s protocol. Oil Red O 
staining kit (Biovision) was used for lipid quantification. Harvested BMCs and bones were 
washed, fixed, processed and stained following the manufacturer’s protocol. BMCs and bone 
were subsequently crushed, strained and resuspended in equal volumes before measuring 
absorbance (OD492). For histological staining, tissues were fixed in 4% paraformaldehyde 
(PFA). PFA-fixed samples were partially decalcified for about 4 hours using a rapid 
decalcifying formic acid/hydrochloric acid mixture (Decalcifying Solution, VWR) and 
embedded in paraffin wax. Sections (5 µm) of the samples were stained with routine 
trichrome, Safranin-O or Verhoeff–Van Gieson stain.
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Quantification of thymic T-cell receptor excision circles (TRECs).
TREC quantification was performed as previously described35. Briefly, thymi were 
harvested from non-irradiated C57BL/6 mice, transplanted mice, and transplanted mice with 
the injected BMC (30 d after conditioning). Total DNA was extracted using TRIZOL 
following tissue homogenization in a Bullet Blender Storm BBX24 instrument (Next 
Advance, Inc.). DNA was quantified by UV-Vis and 1 μg of DNA per sample was used as 
input for real-time PCR. A standard curve of mouse sjTREC plasmid was used to calculate 
the absolute number of single joint TRECS (sjTRECs) per sample.
TCR analysis
Extracted lymphocyte RNA was quantified using UV-Vis. Equimolar amounts of RNA from 
each sample was submitted to iRepertoire for sequencing and bioinformatics analysis, where 
samples were reverse transcribed and amplified using a primer set which specifically 
amplifies beta TCR RNA. The results of the sequencing gave a range of total reads and 
numbers of unique CDR3s for each sample.
Vaccination and non-specific T-cell-stimulation study
30 days after transplantation, animals were immunized with a bolus vaccine containing 100 
μg ovalbumin (OVA), 100 μg CpG-ODN and 1 μg GM-CSF. After 10 d, animals were 
challenged with an intravenous injection of ovalbumin. On Day 12, spleens were collected 
from euthanized mice in the vaccination studies. Splenocytes were isolated by mechanical 
disruption of the spleen against 70-μm cell strainers. Red blood cells in the harvested tissues 
were lysed and leukocytes were prepared for analysis. For unspecific stimulation, cells were 
incubated for 5 h with PMA (10 ng/mL) + ionomycin (2 µM). Brefeldin A (10 µg/mL) was 
added after 2 h of incubation. The cells were then harvested, washed, and stained with 
fluorochrome-conjugated antibodies to T-cell surface antigens. Subsequently, cell were fixed 
and permeabilized with fixation/permeabilization solution kit reagents (BD) and stained with 
IFN-γ, TNF-α-specific antibodies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Alginate-PEG-DLL4 based bone marrow cryogel (BMC) presents DLL4 and BMP-2, and 
preferentially expands common lymphoid progenitors (CLPs). (a) Schematic for the 
fabrication of covalently crosslinked BMC. (b) Representative cross sectional scanning 
electron micrograph (SEM) image of a BMC. Scale bar, 1mm. (c) Representative SEM of 
the pore shape and structure within the cross section of the BMC. Scale bar = 200μm. (d) 
Release kinetics of the encapsulated BMP-2 (red line) and covalently tethered DLL4 (green 
line) (n=5 per group) (e) Surface plasmon resonance measuring the binding kinetics of the 
DLL4 before and after modification with the methacrylate linker. (f) In vitro differentiation 
of isolated mouse and human hematopoietic stem and progenitor cells into CLPs as a 
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function of the degree of functionalization of methacrylate groups on the polymer backbone 
(n = 5). (g) Proportion of Lin- common lymphoid and myeloid mouse progenitor cells 
quantified in growth medium, blank, single factor and dual factor BMCs. Images and pore 
size quantification in b, c are representative of ten independent replicates. Data in d, f, g 
represent the mean ± s.d. of five experimental replicates and are representative of three 
independent experiments. Distinct samples were assayed individually.
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Figure 2. 
In vivo deployment and host integration of BMCs. (a) Schedule of administration of L-TBI, 
HSCT and simultaneous injection of the BMCs. B6 mice were irradiated with 1000 cGy (1 
dose) and subsequently transplanted with 5 × 105 lineage depleted syngeneic GFP BM cells 
within 48 hours after L-TBI. (b) The volume of the BMC nodule in vivo as a function of 
time post-delivery with various combinations of the BMP-2 and DLL-4 included in the 
BMC. (c) Confocal microscopy image of donor GFP+ cells (green) identified within the 
BMC (red) (d) Representative microcomputed tomography (microCT, scale bar = 1mm) 
imaging and (e) histology (scale bar = 1mm) of the dual functionalized BMC at 3 weeks 
post injection with the bone shell (green arrow) and the hematopoietic tissue (yellow arrow). 
(f) Images of the BMC (blue) in the subcutaneous tissue at various timepoints post-injection. 
(g) Histological Verhoeff–Van Gieson stained sections of the BMC with blood vessels 
identified (blue arrows) at Day 10, 30, 40 and 90 post-transplant and (h) quantification of the 
blood vessel density within these sections. (i) Histological Safranin-O stained sections of the 
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BMC with alginate identified (red thread-like staining) at Day 10, 20, 40, 60 and 90 post-
transplant and (j) quantification of the accessible area of alginate within these sections. Data 
in b represent the mean ± s.d. of five experimental replicates and are representative of two 
independent experiments. (*P < 0.05, ** P < 0.01, ***P < 0.001, analysis of variance 
(ANOVA) with a Tukey post hoc test). Images in c-g, i are representative of four 
independent samples. Data in h, j represent the mean ± s.d. from eight samples and are 
representative of two independent experiments. Distinct samples were assayed individually.
Shah et al. Page 20
Nat Biotechnol. Author manuscript; available in PMC 2019 August 11.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 3. 
In vivo recruitment of donor cells to BMC and enhanced seeding of thymic progenitors. (a) 
Total number and type of donor derived, GFP+ cells in the BMC containing combinations of 
BMP-2 and DLL-4 and blank BMCs. (b) Absolute number of donor GFP+ CLPs and the 
percentage of Ly6D- CLPs in BMP-2- and dual factor- BMCs. (c) Schematic of 
experimental setup for surgical transplantation of harvested BMCs from post-HSCT mice 
into sub-lethally irradiated mice. (d) DP, SP CD4+ and SP CD8+ cells quantified in the 
thymus 20-days post surgical transplantation of BMC. (e) Total number of early T-lineage 
progenitors (ETP; CD44+CD25−c-kit+) quantified as a function of lineage-depleted 
transplanted cell dose compared with BMC treatment with the lowest cell dose at multiple 
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time points post transplant with representative FACS plots (five experimental replicates at 
each time point, 2 independent experiments). (f-k) Total number of early T-lineage 
progenitors (ETP; CD44+CD25−c-kit+), DN2 (CD44+CD25−), DN3 (CD44+CD25−), DP, 
SP4, SP8 thymocyte subsets compared across different treatment conditions at multiple time 
points post transplant. For a, b, f-k the mice were transplanted with 5 × 105 lineage depleted 
syngeneic GFP BM cells within 48 hours after L-TBI (1 × 1000 cGy). In c, d an initial set of 
mice were transplanted with 5 × 105 lineage depleted syngeneic GFP BM cells within 48 
hours after L-TBI. A subsequent set of mice received SL-TBI (1 × 500 cGy) without a 
subsequent cell transplant. In e, the mice were transplanted with 5 × 104 to 5 × 105 lineage 
depleted GFP cells. All groups are compared with transplant only control (*P < 0.05, ** P < 
0.01, ***P < 0.001, analysis of variance (ANOVA) with a Tukey post hoc test). Data in a 
represents the mean ± s.d. of ten mice per group and are representative of two independent 
experiments. Data in b, d-k represent the mean ± s.d. from five mice per group, and at each 
time point in d-k and are representative of at least two independent experiments. In a all 
groups are compared with the blank gel control group. Comparisons are with the lowest cell 
dose group in e and the transplant only group in d-k. (*P < 0.05, ** P < 0.01, ***P < 0.001, 
analysis of variance (ANOVA) with a Tukey post hoc test). Distinct samples were assayed 
individually.
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Figure 4. 
Enhancement of T-cell reconstitution mediated by the BMC (a) The sum of CD3+CD4+ and 
CD3+CD8+ in the peripheral blood of mice post-HSCT. B6 mice were irradiated with 1 × 
1000 cGy L-TBI dose. Mice were subsequently transplanted with 5 × 105 lineage depleted 
syngeneic GFP BM cells within 48 hours after L-TBI and treated as indicated in the figure. 
Measurement of the recovery in CD4+ to CD8+ T-cell ratios in the (b) blood, (c) spleen and 
(d) bone marrow, as a function of time, with non-irradiated mice as for comparison for the 
same groups as in (a). In (a - d) Post-HSCT mice with no BMC (Transplant only), post-
HSCT mice treated with bolus BMP-2 and DLL-4 injection, a BMC containing BMP-2 
(BMP-2 BMC), and post-HSCT mice treated with a BMC containing BMP-2 and DLL4 
(Dual BMC) were analyzed. In (e-j) B6 mice were irradiated with 500 cGy SL-TBI and 
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subsequently transplanted with 5 × 105 lineage-depleted bone marrow cells within 48 hours 
post-radiation. Total number of (e) DP (f) SP4 and (g) SP8 thymocytes and peripheral (h) 
CD4+ and (i) CD8+ T-cells and (j) B-cells in the spleens of SL-TBI syn-HSCT mice that 
were treated with and without a dual BMC 28 days post-transplant. Data in a-d represent the 
mean ± s.d. of n = 8 mice per group for each time point and are representative of at least 3 
independent experiments. Data in e-j represent the mean ± s.d. of n= 10 mice and are 
representative of 2 independent experiments. (*P < 0.05, ** P < 0.01, ***P < 0.001, analysis 
of variance (ANOVA) with a Tukey post hoc test).
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Figure 5. 
Enhanced reconstitution of T-cells and mitigation of GVHD in NSG-BLT mice and in mice 
after allogeneic HSCT. Reconstitution of (a) CD3+ T-cells and (b) CD19+ B-cells with (c) 
CD4+:CD8+ ratio in humanized NSG-BLT mice with exemplary flow cytometry plots at day 
75. (d) Survival rate in NSG-BLT mice (n = 10 per group) and (e) Reconstitution of human 
regulatory T-cells in the thymus and spleen of NSG-BLT mice with representative flow 
cytometry plots. In (a) through (e) xenogeneic humanized BLT (bone marrow‒liver‒
thymus) mice were generated and used as described previously23. Mice with no BMC 
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(NSG-BLT) and mice with the Dual BMC (NSG-BLT + Dual BMC) with human donor 
tissue from the same source were analyzed. (f) Survival rate and (g) reconstitution of donor-
derived regulatory T-cells in the thymus and spleen of allogeneically transplanted Balb/c 
mice. In f, g BALB/cJ recipient mice received 850 cGy of L-TBI. Within 48 hours post-
radiation, mice were transplanted with allogeneic GFP 5 × 105 lineage depleted GFP BM 
cells + 106 GFP splenocytes. One group was simultaneously treated with the dual BMC. (h-
l) Comparison of T-cell reconstitution in mice treated with BMC or OP9-DL1 derived pro-T-
cells. Balb/cJ recipient mice received 850Gy L-TBI and were either provided OP9-DL1 
culture derived 5 × 106 allogeneic GFP T-cell progenitors + 103 syngeneic HSCs or dual 
BMC + 5 × 105 lineage depleted allogeneic GFP BM cells. Total number of (h) DP and (i) 
SP4 and (j) SP8 thymocytes in the thymus and peripheral (k) CD4+ and (l) CD8+ T-cells in 
the spleen of transplanted mice 28 days post-transplant. Data in a-d are the mean ± s.d.of at 
n = 10 mice at the start of the study and are representative of 3 donors. Data in (e,g) and f 
are the mean ± s.d.of n = 7 and n=10 mice respectively and are representative of 2 
independent experiments. Data in h-l are mean ± s.d. of n= 10 mice, representative of 2 
independent experiments. Distinct samples were assayed individually. (*P < 0.05, ** P < 
0.01, ***P < 0.001, analysis of variance (ANOVA) with a Tukey post hoc test).
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Figure 6. 
Quantitative analysis of T-cell output, the immune repertoire and vaccination in mice with 
regenerated T-cells. T-cell receptor excision circle analysis from the (a) isolated thymus and 
(b) spleen in mice. (c) The diversity in antigen receptors of T-cells as analyzed by the 
sequenced V and J segments of the CDR3 beta chain in the BMC and transplant mice. Each 
bar represents a single clone. The plot provides depth (length of bar) and diversity (number 
of bars) of T-cells in the mice. Samples were pooled from five mice for each group and the 
combined data are represented. (d) Schedule of analyzing antigen-specific donor T-cell 
response through vaccination. (e) Donor SIINFEKL+CD8+ T-cells enumerated in vaccinated 
mice after syn-HSCT and (f) allo-HSCT. (g, h) At day 22 and 42 after HSCT, splenocytes of 
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the OP9-DL1 T-cell precursor group and the dual-BMC treated group were stimulated and 
stained for surface markers and intracellular cytokines using antibodies specific for CD45.1, 
CD4, IFN-γ and TNF-α. Cells were gated on CD4+ or CD8+ donor cells, and analyzed for 
IFN-γ– and TNF-α–positive cells. In a-c and e, B6 recipients received 1000 cGy L-TBI and 
5 × 105 lineage depleted syngeneic GFP BM cells. Post-HSCT mice with no BMC 
(Transplant only), post-HSCT mice treated with a BMP-2 BMC, and post-HSCT mice 
treated with a Dual BMC were analyzed and compared with non-irradiated mice that had not 
received a transplant or vaccine. In (f-h) Balb/cJ recipient mice received 850Gy L-TBI and 
were either provided OP9-DL1 culture derived 5 × 106 allogeneic GFP T-cell progenitors + 
103 syngeneic HSCs or dual BMC + 5 × 105 lineage depleted allogeneic GFP BM cells. 
Data in a, b are mean ± s.d. of n = 10 mice, data in e, f are mean ± s.d. of n = 5 mice, data in 
(g, h) are mean ± s.d. of n = 7 mice. All experiments are representative of two independent 
experiments. (*P < 0.05, ** P < 0.01, ***P < 0.001, analysis of variance (ANOVA) with a 
Tukey post hoc test).
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